About
Introduction
Prof. dr. Harry Hendrikse is Hospital Pharmacist -Clinical Pharmacologist and full Professor at Translational Radiopharmacology. He is also Director of Cyclotron Rotterdam BV (a radiopharmaceutical holding of Erasmus MC).
He is chair of the Radiopharmaceutical Sciences Committee (RSC) of the European Association of Nuclear Medicine and member of the Medical Ethical Board of Erasmus MC.
His research focus on radiolabelled diagnostic drug development and clinical radiopharmacological evaluation performing PET imaging studies with existing or new radiolabelled drugs in several groups of patients, especially in oncology. Furthermore, we develop radiolabelled drugs for therapy of cancer patients (e.g. prostate and neuro endocrine tumors). With radiolablled drugs for diagnostic PET imaging, together with radiolabled drugs for therapy, we contributed to treatments of oncology patients by theranostics, an important topic in nuclear medicine.
He supervises several master students and PhD students, where 10 are finished. He is author of more than 185 publications.
Field(s) of expertise
- Clinical Radiopharmacology
- Radiopharmaceutical drug development
- Theranostics
- Pharmacokinetic modelling of radiopharmaceuticals
Education and career
Publications
Teaching activities
- Lectures for Master Pharmacy students of University of Utrecht about developments in Radiopharmacy and Radiopharmacology . During this course master students pharmacy are trained in radiopharmaceutical drug development, where basic principles, but also new insights in drug development and results in clinical studies are teached.
- PAO (Post Academisch Onderwijs) course “Radiofarmacie en Nucleaire Geneeskunde” for hospital pharmacist and nuclear physicians in training. During this (practical and theoretical) course basic principles for radiopharmaceuticals, including preparation and legislation are trained (in collaboration with TU Delft).
- Accompany theses master Pharmacy students and Medicine students.
- Accompany internship master Pharmacy students and hospital pharmacists in training. During their training the students work within the radiopharmacy department to get knowledge about practical and theoretical radiopharmaceutical aspects.
- As chair of the Radiopharmaceutical Committee of Europan Association of Nuclear Medicine (EANM), he develops radiopharmaceutical courses for radiopharmacists in Europe.
Other positions
- Chair Radiopharmacy Sciences Committee European Association of Nuclear Medicine (EANM)
- Member Medical Ethical Board of Erasmus MC
Scholarships, grants, and awards
- The use of [11C]erlotinib for visualization of EGFR mutated tumors and metastases in NSCLC. A feasibility study (VU 2012-5550, €553.000,00)
- Can tumor uptake of [18F]afatinib in NSCLC patients be quantified, and does [18F]afatinib uptake identify patients who will benefit from afatinib therapy? (Boehringer Ingelheim, €291.000,00)
- [11C]osimertinib-PET/CT to identify T790M positive tumor lesions in patients that are T790M negative in a single tumor biopsy and a circulating tumor DNA sample (Astra Zeneca, €493.000,00)
- Guiding personalized therapy of patients with metastatic prostate cancer using a ·novel PET tracer: validation of radiolabeled PSMA (CCA/V-ICI, €194.000,00)
- Efficacy and Safety of 177Lu-edotreotide Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET patients) (ITG/ABX, €520.000,00)
- Target Site Physiologically-based Pharmacokinetic Modeling in Primary and Metastatic brain Tumors to enable Tyrosine Kinase Inhibition precision Oncology & Personalized Dosing (KWF 2023-3 DEV/15486, €1.279.198,00)
